The US tech universe.
378 companies, 39 frontiers.

Neuralink is developing implantable brain-computer interfaces — a coin-sized device with ultra-fine threads that read and write neural signals, implanted by a surgical robot it also builds. Its first goal is to let people with paralysis control computers and devices directly with their thoughts, with early human trials underway. Longer term, the company aims to restore lost senses and movement and, ultimately, to create a high-bandwidth link between the human brain and machines.

Blackrock Neurotech is one of the longest-running brain-computer interface companies, whose implant systems have let people with paralysis control computers, robotic arms and digital devices using only their thoughts — with users reportedly typing and decoding speech directly from neural activity. Its hardware is also the research workhorse used by labs worldwide to study the brain. As BCIs move from research toward approved clinical products, the company aims to bring thought-controlled assistive technology to patients with paralysis and other neurological conditions.

Emotiv (San Francisco) is a non-invasive neurotechnology and bioinformatics company that makes wireless, wearable EEG headsets and a brain-data platform used in research, workplace wellness and consumer applications. Rather than implants, it reads brain activity from sensors on the scalp. Its aim is to build the cognitive-data infrastructure that turns everyday brain measurement into usable insight.

Kernel develops non-invasive technology that measures brain function from outside the head, turning a roughly 30-minute scan into longitudinal reports on cognition and 'brain age' that clinics and individuals can track over time. Unlike implanted brain-computer interfaces, its approach is wearable and aimed at routine, repeatable measurement of brain health. The goal is to make objective brain measurement as normal as tracking steps or sleep, supporting earlier detection and better-targeted interventions.

Neurable (Boston) is a non-invasive, consumer brain-computer interface company — unlike the surgical-implant players in this space, it builds everyday EEG sensors into ordinary products like headphones to read brain signals from outside the skull. Its first products focus on focus-tracking and neuro-wellness in wearable form factors. The goal is to make brain-sensing a mainstream, no-surgery feature of the devices people already use.

NeuroSky (San Jose, CA) is a non-invasive neurotechnology company that makes low-cost, single-sensor EEG and biosensor chips used in consumer headsets, toys, education and wellness products. It pioneered bringing affordable dry-electrode brainwave sensing to mass-market devices. Its role in this frontier is the budget, high-volume end of consumer BCI rather than the surgical-implant cutting edge.

OpenBCI (Brooklyn, NY) is a non-invasive, open-source brain-computer interface company providing biosensing hardware, boards and electrodes for researchers, developers and hobbyists. Its Galea platform combines EEG, EMG, eye and other biometric sensors with mixed-reality headsets for immersive neuro-applications. By keeping its tools open and accessible, the goal is to democratise neuro-research and human-computer interaction beyond the surgical-implant labs.

Paradromics builds a brain-computer interface that records activity from individual neurons at very high resolution, then uses AI to decode that brain data — with its first product, Connexus, aimed at letting people who cannot speak (due to ALS, stroke or spinal-cord injury) communicate through digital devices. The implant is investigational and now cleared by the FDA to begin a human clinical study. If the platform scales across more brain regions, the company envisions applications spanning paralysis, chronic pain, addiction and mental-health conditions.

Precision Neuroscience, founded by Neuralink alumni, makes a thin-film brain-computer interface that lays a flexible micro-electrode array on the surface of the brain rather than pushing electrodes into it — designed to be removable and upgradable without damaging tissue. Its first use is helping people with paralysis operate computers and devices by thought, and its core cortical interface has received FDA 510(k) clearance. The company's bet is that a high-bandwidth but minimally harmful connection can eventually expand across the brain to treat far more conditions.

Science Corporation, founded by Neuralink co-founder Max Hodak, is a clinical-stage neural-engineering company building a full stack of brain-interface technologies — led by PRIMA, a retinal implant designed to restore functional vision to people blinded by advanced macular degeneration. It also develops biohybrid neural interfaces and operates a 'Foundry' that supplies its microfabrication and neural-engineering capabilities to other researchers. If its vision-restoration and biohybrid platforms prove out, the company aims to treat a broad range of conditions for which there are currently no options.

Synchron builds an implantable brain-computer interface that, uniquely, requires no open-brain surgery — its Stentrode device is threaded into a blood vessel near the brain through the jugular vein, the way a cardiac stent is placed. It is in clinical trials in the US and Australia aiming to restore communication and digital control for people living with paralysis. Because it sidesteps the skull entirely, Synchron's 'interventional' approach is designed to scale brain interfaces to potentially millions of patients rather than a handful of surgical cases.

Boom Supersonic is developing Overture, a commercial supersonic airliner intended to fly passengers roughly twice as fast as today's jets, alongside its own purpose-built Symphony engine; it already holds orders from United, American and Japan Airlines. Its XB-1 demonstrator has flown faster than the speed of sound, proving out the core technology. Boom is also spinning its supersonic engine work into a natural-gas turbine ('Superpower') aimed at powering AI data centers — a notable adjacency flagged for review.

Hermeus is a high-speed aircraft manufacturer focused on rapidly designing, building and testing high-Mach and hypersonic aircraft, working directly with the US Department of War. Its reusable Quarterhorse aircraft is built to make routine, affordable testing in extreme flight regimes possible, with the Darkhorse program aimed at operational hypersonic capability. The thesis is that fast, iterative hardware development can give the US and its allies a durable speed advantage in defense and, eventually, civil high-speed flight.

Spike Aerospace is designing the S-512 Diplomat, a supersonic business jet built to fly without the disruptive sonic boom that grounded Concorde over land. The promise is to cut long-haul flight times roughly in half — New York to London in hours, not most of a day — while engineering the noise down to a soft thump. If it reaches market, quiet supersonic travel could reopen overland routes and reshape how the time-pressed move around the world.

Venus Aerospace is developing a rotating detonation rocket engine and a hypersonic aircraft designed to fly at extreme speed and altitude. The vision is point-to-point travel where journeys that take many hours today could shrink to roughly an hour, plus engines that could serve high-speed defense and space-access markets. It is still in flight-test territory, but a working hypersonic engine would open a frontier of travel and propulsion that is currently impossible at commercial scale.

Commonwealth Fusion Systems, an MIT spin-out, is building SPARC — a compact, high-field tokamak it says will be the first fusion device to produce more energy than it consumes — using a new generation of high-temperature superconducting (REBCO) magnets that allow a much smaller machine than earlier designs. After SPARC, it plans ARC, intended to be the world's first fusion plant delivering net electricity to the grid. If it works, CFS aims to turn fusion from a perpetual lab promise into mass-producible, carbon-free baseload power.

Focused Energy is commercializing direct-drive laser fusion — the same inertial-confinement approach that achieved scientific ignition at the U.S. National Ignition Facility in 2021 — to build a clean, near-limitless power source. Founded by scientists who worked on that ignition milestone and engineers from the laser and semiconductor worlds, the company is designing the lasers, targets and plant systems needed to turn that lab result into electricity on the grid. Its stated mission is to decouple energy production from resource consumption, with a roadmap targeting a pilot plant and first grid power in the 2030s.

Helion Energy is pursuing a distinctive fusion approach: it accelerates two rings of plasma toward each other at high speed, compresses them with powerful pulsed magnets until they fuse, and then recaptures the resulting energy directly as electricity rather than via steam turbines. It uses a deuterium/helium-3 fuel cycle and has built and tested seven prototypes, with its Polaris machine aimed at demonstrating electricity from fusion and Orion targeted as its first grid power plant. The pitch is compact, lower-cost, mass-deployable fusion — underscored by a previously announced power agreement with Microsoft.

Pacific Fusion is building a fusion power system using 'pulsed magnetic inertial fusion' — rapidly squeezing tiny fuel capsules with an intense, fast-rising magnetic field to fuse hydrogen into helium and release energy, repeated over and over like the strokes of a piston engine. Its design is deliberately modular, built from thousands of identical parts and common materials to keep manufacturing affordable. The goal is a system that produces more fusion energy than the total energy put in — a path to limitless, clean, on-demand power if it can be made commercially viable.

Realta Fusion, spun out of the University of Wisconsin–Madison, is developing compact, modular fusion energy systems based on the magnetic-mirror confinement concept — applying next-generation high-temperature superconducting magnets to a mature design to reach the grid faster. Rather than chasing one giant reactor, it aims to build prefabricated modules that can be assembled to power 'hard-to-decarbonize' industrial heat and electricity needs. The goal is fusion units competitive on cost with conventional fuels, offering industry a zero-carbon energy source.

SHINE Technologies is taking a step-by-step, revenue-generating path to fusion: rather than building a reactor first, it commercializes the underlying nuclear technology in stages — neutron testing for aerospace and defense components, producing medical isotopes for diagnostics and cancer treatment, recycling used nuclear fuel, and finally fusion energy. Each business funds the next and builds the industrial capability needed for power generation. The long-term goal is clean, abundant fusion electricity, reached by proving market value at every step rather than waiting for a single breakthrough.

TAE Technologies, founded in 1998, is pursuing a distinctive approach to commercial fusion power using hydrogen-boron fuel and a field-reversed-configuration plasma design, aiming for clean energy with the cleanest environmental profile. Its breakthroughs in particle accelerators have spun off two real businesses today: battery and e-mobility power management (TAE Power Solutions) and a precision cancer radiation therapy based on Boron Neutron Capture Therapy (TAE Life Sciences). If its fusion roadmap succeeds, the goal is compact, cost-effective carbon-free power capable of supplying the grid for centuries.

Type One Energy is commercializing stellarator fusion — a twisted magnetic-confinement design its team helped pioneer at the HSX and W7-X experiments — to generate steady, baseload clean electricity. The company is the technology provider and equipment manufacturer for the Tennessee Valley Authority's Infinity Two project, which it describes as the world's first grid-scale commercial fusion power plant, and has submitted an initial licensing application for a site near Oak Ridge. Using proven enabling technologies like high-temperature superconducting magnets and exascale computing, it is targeting commercial fusion power on the grid by the mid-2030s.

Zap Energy is pursuing fusion with a distinctive approach that needs no massive magnets or lasers: it uses a 'sheared-flow-stabilized Z-pinch,' running a powerful electric current through a thin column of plasma so the current's own magnetic field compresses and confines it. The company has now broadened into an integrated nuclear strategy — 'fission today, fusion tomorrow.' Its U.S. Department of Energy-approved fusion pilot plant preconceptual design marks a step toward a simpler, potentially lower-cost route to commercial fusion power.

Drills deep to tap ultra-hot rock for clean, always-on power — the geothermal cousin of fusion.

Altos Labs is a biotech pursuing 'cellular rejuvenation programming' — the science of resetting aged or damaged cells back to a healthier, more youthful state to restore their resilience. Its stated mission is to reverse disease, injury and the disabilities that build up over a lifetime by repairing cells at the source rather than just treating symptoms. If the approach translates from early experiments to medicine, it could open an entirely new way to treat age-related disease — backed by one of the largest launch fundings in biotech history.

BioAge Labs mines decades of human aging data to find the molecular switches that drive metabolic disease, then turns those insights into drugs — its lead programs target chronic inflammation linked to cardiovascular risk and an 'exercise-mimic' pathway for obesity. Rather than chasing aging in the abstract, it aims at the diseases of getting older where the market is already enormous, like obesity and heart disease. If its human-first discovery engine keeps validating, it points toward a future where the biology of aging itself becomes a drug-discovery platform.

Gilgamesh Pharma is a clinical-stage neuroscience biotech designing novel chemical entities — including next-generation psychedelic, NMDA and ibogaine-derived compounds — to treat psychiatric disease by engaging the brain's own plasticity instead of just masking symptoms. Its pipeline spans depression, anxiety, schizophrenia and addiction, and its lead asset bretisilocin (GM-2505) was acquired by AbbVie, validating its discovery platform. The promise: rapid-acting, durable mental-health therapies that could move psychiatry beyond lifelong symptom management toward lasting change.

Human Longevity — co-founded by genome-sequencing pioneer Dr. J. Craig Venter — combines whole-genome sequencing, whole-body MRI, and 100+ biomarkers into a single AI-interpreted health workup designed to catch disease years before symptoms appear. The premise is that most serious illness develops silently for years, and that reading your genome plus deep imaging can surface cardiovascular, cancer, metabolic, and neurodegeneration risk while it's still preventable. It's an early bet on a future where prevention is driven by continuously re-analyzed personal biological data, not annual check-ups.

Life Biosciences is pioneering 'cellular rejuvenation' through epigenetic restoration — reverting aged or injured cells to a younger, healthier state to reverse age-related disease. Its lead program, ER-100, targets optic neuropathies (vision loss) and has received FDA clearance to begin human trials. The promise: because aging is the biggest risk factor for most chronic disease, a platform that can restore youthful cell function could one day address many age-related conditions at their common root.